Special considerations in the evaluation and management of breast cancer in men

Current Problems in Cancer

Volumn 40, Issue 2-4, 2016, Pages 163-171

  Massarweh, Suleiman Alfred ^a,b   Choi, Gloria L ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Androgen receptor; BRCA2; Breast cancer in men; Estrogen receptor; Tamoxifen

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADJUVANT THERAPY; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER PATIENT; GENE AMPLIFICATION; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; HEREDITY; HORMONAL REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METASTATIC BREAST CANCER; POSTMENOPAUSE; REVIEW; RISK FACTOR; SYSTEMIC THERAPY; TUMOR SUPPRESSOR GENE; BREAST TUMOR; GENETICS;

BREAST NEOPLASMS, MALE; HUMANS; MALE; RISK FACTORS;

EID: 84994047687     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2016.09.003     Document Type: Review

References (75)

1. 1 Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J Clin 66 (2016), 7–30.
2. 2 Giordano, S.H., Cohen, D.S., Buzdar, A.U., Perkins, G., Hortobagyi, G.N., Breast carcinoma in men: a population-based study. Cancer 101 (2004), 51–57.
3. 3 Anderson, W.F., Devesa, S.S., Breast carcinoma in men. Cancer 103 (2005), 432–433.
4. 4 Sorensen, H.T., Friis, S., Olsen, J.H., Thulstrup, A.M., Mellemkjaer, L., Linet, M., et al. Risk of breast cancer in men with liver cirrhosis. Am J Gastroenterol 93 (1998), 231–233.
5. 5 Ewertz, M., Holmberg, L., Tretli, S., Pedersen, B.V., Kristensen, A., Risk factors for male breast cancer—a case-control study from Scandinavia. Acta Oncol 40 (2001), 467–471.
6. 6 Hsing, A.W., McLaughlin, J.K., Cocco, P., Co Chien, H.T., Fraumeni, J.F. Jr, Risk factors for male breast cancer (United States). Cancer Causes Control 9 (1998), 269–275.
7. 7 McClure, J., Higgins, C.C., Bilateral carcinoma of male breast after estrogen therapy. J Am Med Assoc 146 (1951), 7–9.
8. 8 Thellenberg, C., Malmer, B., Tavelin, B., Gronberg, H., Second primary cancers in men with prostate cancer: an increased risk of male breast cancer. J Urol 169 (2003), 1345–1348.
9. 9 Symmers, W.S., Carcinoma of breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics. Br Med J 2 (1968), 83–85.
10. 10 Thomas, D.B., Jimenez, L.M., McTiernan, A., Rosenblatt, K., Stalsberg, H., Stemhagen, A., et al. Breast cancer in men: risk factors with hormonal implications. Am J Epidemiol 135 (1992), 734–748.
11. 11 Evans, D.B., Crichlow, R.W., Carcinoma of the male breast and Klinefelter's syndrome: is there an association?. CA Cancer J Clin 37 (1987), 246–251.
12. 12 Rosenbaum, P.F., Vena, J.E., Zielezny, M.A., Michalek, A.M., Occupational exposures associated with male breast cancer. Am J Epidemiol 139 (1994), 30–36.
13. 13 Andersen, J.A., Gram, J.B., Male breast at autopsy. Acta Pathol Microbiol Immunol Scand A 90 (1982), 191–197.
14. 14 Brinton, L.A., Carreon, J.D., Gierach, G.L., McGlynn, K.A., Gridley, G., Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database. Breast Cancer Res Treat 119 (2010), 185–192.
15. 15 Brinton, L.A., Cook, M.B., McCormack, V., Johnson, K.C., Olsson, H., Casagrande, J.T., et al. Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. J Natl Cancer Inst, 2014, 106 djt465.
16. 16 Brinton, L.A., Key, T.J., Kolonel, L.N., Michels, K.B., Sesso, H.D., Ursin, G., et al. Prediagnostic sex steroid hormones in relation to male breast cancer risk. J Clin Oncol 33 (2015), 2041–2050.
17. 17 Cook, M.B., Guenel, P., Gapstur, S.M., van den Brandt, P.A., Michels, K.B., Casagrande, J.T., et al. Tobacco and alcohol in relation to male breast cancer: an analysis of the male breast cancer pooling project consortium. Cancer Epidemiol Biomarkers Prev 24 (2015), 520–531.
18. 18 Olsson, H., Andersson, H., Johansson, O., Moller, T.R., Kristoffersson, U., Wenngren, E., Population-based cohort investigations of the risk for malignant tumors in first-degree relatives and wives of men with breast cancer. Cancer 71 (1993), 1273–1278.
19. 19 Johansen Taber, K.A., Morisy, L.R., Osbahr, A.J. 3rd, Dickinson, B.D., Male breast cancer: risk factors, diagnosis, and management (Review). Oncol Rep 24 (2010), 1115–1120.
20. 20 Ford, D., Easton, D.F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62 (1998), 676–689.
21. 21 Hall, J.M., Lee, M.K., Newman, B., Morrow, J.E., Anderson, L.A., Huey, B., et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250 (1990), 1684–1689.
22. 22 Ding, Y.C., Steele, L., Kuan, C.J., Greilac, S., Neuhausen, S.L., Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat 126 (2011), 771–778.
23. 23 NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High Risk Assessment: Breast and Ovarian Cancers. http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf; 2015.
24. 24 Giordano, S.H., A review of the diagnosis and management of male breast cancer. Oncologist 10 (2005), 471–479.
25. 25 Erlichman, C., Murphy, K.C., Elhakim, T., Male breast cancer: a 13-year review of 89 patients. J Clin Oncol. 2 (1984), 903–909.
26. 26 Giordano, S.H., Buzdar, A.U., Hortobagyi, G.N., Breast cancer in men. Ann Intern Med 137 (2002), 678–687.
27. 27 Guinee, V.F., Olsson, H., Moller, T., Shallenberger, R.C., van den Blink, J.W., Peter, Z., et al. The prognosis of breast cancer in males. A report of 335 cases. Cancer 71 (1993), 154–161.
28. 28 Crichlow, R.W., Carcinoma of the male breast. Surg Gynecol Obstet 134 (1972), 1011–1019.
29. 29 Braunstein, G.D., Gynecomastia. N Engl J Med 328 (1993), 490–495.
30. 30 Chau, A., Jafarian, N., Rosa, M., Male breast: clinical and imaging evaluations of benign and malignant entities with histologic correlation. Am J Med, 2016, 10.1016/jamjmed2016.01.009 [Epub Feb 1, 2016].
31. 31 Amoroso WL, R.G.F., Treves, N., Serous and serosanguinous discharge from the male nipple. Arch Surg 73 (1956), 319–329.
32. 32 Cardoso, F., Bartlett, J., Slaets, L., van Deurzen, C., van Leewen-Stok, E., Porter, P., et al. Abstract S6-05: characterization of male breast cancer: first results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program. Cancer Res, 75, 2015 S6-05-S6.
33. 33 Sanchez, A.G., Villanueva, A.G., Redondo, C., Lobular carcinoma of the breast in a patient with Klinefelter's syndrome. A case with bilateral, synchronous, histologically different breast tumors. Cancer 57 (1986), 1181–1183.
34. 34 Nance, K.V., Reddick, R.L., In situ and infiltrating lobular carcinoma of the male breast. Hum Pathol 20 (1989), 1220–1222.
35. 35 De Rosa, G., Giordano, G., Boscaino, A., Terracciano, L., Donofrio, V., De Dominicis, G., Intracystic papillary carcinoma of the male breast. A case report (histochemical, immunohistochemical and ultrastructural study). Tumori 78 (1992), 37–42.
36. 36 Taglietti, L., Vettoretto, N., Blanzuoli, L., Giovanetti, M., Granular cell tumor of the male breast. Updates Surg 63 (2011), 139–142.
37. 37 Masci, G., Caruso, M., Caruso, F., Salvini, P., Carnaghi, C., Giordano, L., et al. Clinicopathological and immunohistochemical characteristics in male breast cancer: a retrospective case series. Oncologist 20 (2015), 586–592.
38. 38 Chavez-Macgregor, M., Clarke, C.A., Lichtensztajn, D., Hortobagyi, G.N., Giordano, S.H., Male breast cancer according to tumor subtype and race: a population-based study. Cancer 119 (2013), 1611–1617.
39. 39 Rudlowski, C., Friedrichs, N., Faridi, A., Fuzesi, L., Moll, R., Bastert, G., et al. Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 84 (2004), 215–223.
40. 40 Wang-Rodriguez, J., Cross, K., Gallagher, S., Djahanban, M., Armstrong, J.M., Wiedner, N., et al. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol 15 (2002), 853–861.
41. 41 Alqaisi, A., Chen, L., Romond, E., Chambers, M., Stevens, M., Pasley, G., et al. Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research. Breast Cancer Res Treat 148 (2014), 437–444.
42. 42 Piscuoglio, S., Ng, C.K., Murray, M.P., Guerini-Rocco, E., Martelotto, L.G., Geyer, F.C., et al. The genomic landscape of male breast cancers. Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2840 [published online first March 9, 2016].
43. 43 Barlund, M., Kuukasjarvi, T., Syrjakoski, K., Auvinen, A., Kallioniemi, A., Frequent amplification and overexpression of CCND1 in male breast cancer. Int J Cancer 111 (2004), 968–971.
44. 44 Turner, N.C., Ro, J., Andre, F., Loi, S., Verma, S., Iwata, H., et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373 (2015), 209–219.
45. 45 Vetto, J., Jun, S.Y., Paduch, D., Eppich, H., Shih, R., Stages at presentation, prognostic factors, and outcome of breast cancer in males. Am J Surg 177 (1999), 379–383.
46. 46 Zaenger, D., Rabatic, B.M., Dasher, B., Mourad, W.F., Is breast conserving therapy a safe modality for early-stage male breast cancer?. Clin Breast Cancer 16 (2016), 101–104, 10.1016/j.clbc.2015.11.005 [Epub Nov 17].
47. 47 Gennari, R., Renne, G., Travaini, L., Bassi, F., Zurrida, S., Sentinel node biopsy in male breast cancer: future standard treatment?. Eur J Surg 167 (2001), 461–462.
48. 48 Donegan, W.L., Redlich, P.N., Lang, P.J., Gall, M.T., Carcinoma of the breast in males: a multiinstitutional survey. Cancer 83 (1998), 498–509.
49. 49 Zabel, A., Milker-Zabel, S., Zuna, I., Wannenmacher, M., Debus, J., External beam radiotherapy in the treatment of male breast carcinoma: patterns of failure in a single institute experience. Tumori 91 (2005), 151–155.
50. 50 Ribeiro, G., Male breast carcinoma—a review of 301 cases from the Christie Hospital & Holt Radium Institute, Manchester. Br J Cancer 51 (1985), 115–119.
51. 51 Goss, P.E., Reid, C., Pintilie, M., Lim, R., Miller, N., Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955–1996. Cancer 85 (1999), 629–639.
52. 52 Bradley, K.L., Tyldesley, S., Speers, C.H., Woods, R., Villa, D., Contemporary systemic therapy for male breast cancer. Clin Breast Cancer 14 (2014), 31–39.
53. 53 Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381 (2013), 805–816.
54. 54 Howell, A., Cuzick, J., Baum, M., Buzdar, A., Dowsett, M., Forbes, J.F., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365 (2005), 60–62.
55. 55 Buzdar, A.U., Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer. J Clin Oncol 25 (2007), 2147–2148.
56. 56 van de Velde, C.J., Rea, D., Seynaeve, C., Putter, H., Hasenburg, A., Vannetzel, J.M., et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377 (2011), 321–331.
57. 57 Osborne, C.K., Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer. Endocr Relat Cancer 6 (1999), 271–276.
58. 58 Harlan, L.C., Zujewski, J.A., Goodman, M.T., Stevens, J.L., Breast cancer in men in the United States: a population-based study of diagnosis, treatment, and survival. Cancer 116 (2010), 3558–3568.
59. 59 Eggemann, H., Ignatov, A., Smith, B.J., Altmann, U., von Minckwitz, G., Rohl, F.W., et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat 137 (2013), 465–470.
60. 60 Korde, L.A., Zujewski, J.A., Kamin, L., Giordano, S., Domchek, S., Anderson, W.F., et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 28 (2010), 2114–2122.
61. 61 Zagouri, F., Sergentanis, T.N., Azim, H.A. Jr., Chrysikos, D., Dimopoulos, M.A., Psaltopoulou, T., Aromatase inhibitors in male breast cancer: a pooled analysis. Breast Cancer Res Treat 151 (2015), 141–147.
62. 62 Maugeri-Sacca, M., Barba, M., Vici, P., Pizzuti, L., Sergi, D., De Maria, R., et al. Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. Breast Cancer Res Treat 147 (2014), 227–235.
63. 63 Pagani, O., Regan, M.M., Walley, B.A., Fleming, G.F., Colleoni, M., Lang, I., et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371 (2014), 107–118.
64. 64 Barh, D., Biomarkers, critical disease pathways, drug targets, and alternative medicine in male breast cancer. Curr Drug Targets 10 (2009), 1–8.
65. 65 Sparano, J.A., Gray, R.J., Makower, D.F., Pritchard, K.I., Albain, K.S., Hayes, D.F., et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373 (2015), 2005–2014.
66. 66 Albain, K.S., Barlow, W.E., Shak, S., Hortobagyi, G.N., Livingston, R.B., Yeh, I.T., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11 (2010), 55–65.
67. 67 Shak, S., Palmer, G., Baehner, F.L., Millward, C., Watson, D., Sledge, G.W., Molecular characterization of male breast cancer by standardized quantitative RT-PCR analysis: first large genomic study of 347 male breast cancers compared to 82,434 female breast cancers. ASCO Meet Abstr, 27, 2009, 549.
68. 68 Farrow, J.H., Adair, F.E., Effect of orchidectomy on skeletal metastases from cancer of the male breast. Science, 95, 1942, 654.
69. 69 Jaiyesimi, I.A., Buzdar, A.U., Sahin, A.A., Ross, M.A., Carcinoma of the male breast. Ann Intern Med 117 (1992), 771–777.
70. 70 Patterson, J.S., Battersby, L.A., Bach, B.K., Use of tamoxifen in advanced male breast cancer. Cancer Treat Rep 64 (1980), 801–804.
71. 71 Giordano, S.H., Hortobagyi, G.N., Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 24 (2006), e42–e43.
72. 72 Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I.N., Khasanov, R., et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28 (2010), 4594–4600.
73. 73 Agrawal, A., Cheung, K.L., Robertson, J.F., Fulvestrant in advanced male breast cancer. Breast Cancer Res Treat, 101, 2007, 123.
74. 74 Zagouri, F., Sergentanis, T.N., Chrysikos, D., Dimopoulos, M.A., Psaltopoulou, T., Fulvestrant and male breast cancer: a pooled analysis. Breast Cancer Res Treat 149 (2015), 269–275.
75. 75 Di Lauro, L., Pizzuti, L., Barba, M., Sergi, D., Sperduti, I., Mottolese, M., et al. Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. J Hematol Oncol 8 (2015), 1–5.